ReviewVirology2015
Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus.
Review in Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04420260 (Scheme of Primary Prevention of Infection by COVID-19, in Workers), which is not on this map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Severe acute respiratory syndrome coronavirus-2 natural animal reservoirs and experimental models: systematic review.Reviews in medical virology · 2021Pooled it
- Evidence of a wide gap between COVID-19 in humans and animal models: a systematic review.Critical care (London, England) · 2020Pooled it
- Review
- In Silico and In Vitro development of novel small interfering RNAs (siRNAs) to inhibit SARS-CoV-2.Computational and structural biotechnology journal · 2025Article
- COVID-AMD database for coronavirus-infected animal models with comparative analysis tools.Scientific reports · 2024Article
- The Abundant Distribution and Duplication of SARS-CoV-2 in the Cerebrum and Lungs Promote a High Mortality Rate in Transgenic hACE2-C57 Mice.International journal of molecular sciences · 2024Article
- Article
- Characterization of a mouse-adapted strain of bat severe acute respiratory syndrome-related coronavirus.Journal of virology · 2023Article
- In vitro high-content tissue models to address precision medicine challenges.Molecular aspects of medicine · 2023Review
- Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations.Pathogens (Basel, Switzerland) · 2022Review
- Animal models for studying coronavirus infections and developing antiviral agents and vaccines.Antiviral research · 2022Review
- Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants.Biosafety and health · 2022Review
- Antiviral Activity of Medicinal Plants against Human Coronavirus: a systematic scoping review of and experimentations.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
- Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines?Viruses · 2022Article
- Animal models for SARS-CoV-2 and SARS-CoV-1 pathogenesis, transmission and therapeutic evaluation.World journal of virology · 2022Review
- The incubation period of coronavirus disease (COVID-19): A tremendous public health threat-Forecasting from publicly available case data in India.Journal of public affairs · 2021Article
- Overview of Nonhuman Primate Models of SARS-CoV-2 Infection.Comparative medicine · 2021Article
- Article
- An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era.Pathogens (Basel, Switzerland) · 2021Review
- Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Two novel coronaviruses have emerged to cause severe disease in humans. While bats may be the primary reservoir for both viruses, SARS coronavirus (SARS-CoV) likely crossed into humans from civets in China, and MERS coronavirus (MERS-CoV) has been transmitted from camels in the Middle East. Unlike SARS-CoV that resolved within a year, continued introductions of MERS-CoV present an on-going public health threat. Animal models are needed to evaluate countermeasures against emerging viruses. With SARS-CoV, several animal species were permissive to infection. In contrast, most laboratory animals are refractory or only semi-permissive to infection with MERS-CoV. This host-range restriction is largely determined by sequence heterogeneity in the MERS-CoV receptor. We describe animal models developed to study coronaviruses, with a focus on host-range restriction at the level of the viral receptor and discuss approaches to consider in developing a model to evaluate countermeasures against MERS-CoV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.